Zhu Y - Search Results

1

A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy.

Meng L, Zha J, Zhou B, Cao L, Jiang C, Zhu Y, Li T, Lu L, Zhang J, Yang H, Feng J, Gu Z, Tang H, Jiang L, Li D, Lavillette D, Zhang X. Meng L, et al. Among authors: zhu y. PLoS Pathog. 2023 Jan 27;19(1):e1011085. doi: 10.1371/journal.ppat.1011085. eCollection 2023 Jan. PLoS Pathog. 2023. PMID: 36706160 Free PMC article.

2

Recombinant covalently closed circular DNA of hepatitis B virus induces long-term viral persistence with chronic hepatitis in a mouse model.

Li G, Zhu Y, Shao D, Chang H, Zhang X, Zhou D, Gao Y, Lan K, Deng Q. Li G, et al. Among authors: zhu y. Hepatology. 2018 Jan;67(1):56-70. doi: 10.1002/hep.29406. Epub 2017 Nov 15. Hepatology. 2018. PMID: 28749559

3

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.

Zhang C, Wang Y, Zhu Y, Liu C, Gu C, Xu S, Wang Y, Zhou Y, Wang Y, Han W, Hong X, Yang Y, Zhang X, Wang T, Xu C, Hong Q, Wang S, Zhao Q, Qiao W, Zang J, Kong L, Wang F, Wang H, Qu D, Lavillette D, Tang H, Deng Q, Xie Y, Cong Y, Huang Z. Zhang C, et al. Among authors: zhu y. Nat Commun. 2021 Jan 11;12(1):264. doi: 10.1038/s41467-020-20465-w. Nat Commun. 2021. PMID: 33431876 Free PMC article.

4

A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.

Yang Z, Wang Y, Jin Y, Zhu Y, Wu Y, Li C, Kong Y, Song W, Tian X, Zhan W, Huang A, Zhou S, Xia S, Tian X, Peng C, Chen C, Shi Y, Hu G, Du S, Wang Y, Xie Y, Jiang S, Lu L, Sun L, Song Y, Ying T. Yang Z, et al. Among authors: zhu y. Signal Transduct Target Ther. 2021 Nov 3;6(1):378. doi: 10.1038/s41392-021-00810-1. Signal Transduct Target Ther. 2021. PMID: 34732694 Free PMC article.

5

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein.

Xu S, Wang Y, Wang Y, Zhang C, Hong Q, Gu C, Xu R, Wang T, Yang Y, Zang J, Zhou Y, Li Z, Liu Q, Zhou B, Bai L, Zhu Y, Deng Q, Wang H, Lavillette D, Wong G, Xie Y, Cong Y, Huang Z. Xu S, et al. Among authors: zhu y. Emerg Microbes Infect. 2022 Dec;11(1):351-367. doi: 10.1080/22221751.2021.2024455. Emerg Microbes Infect. 2022. PMID: 34964428 Free PMC article.

6

Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.

Li C, Zhan W, Yang Z, Tu C, Hu G, Zhang X, Song W, Du S, Zhu Y, Huang K, Kong Y, Zhang M, Mao Q, Gu X, Zhang Y, Xie Y, Deng Q, Song Y, Chen Z, Lu L, Jiang S, Wu Y, Sun L, Ying T. Li C, et al. Among authors: zhu y. Cell. 2022 Apr 14;185(8):1389-1401.e18. doi: 10.1016/j.cell.2022.03.009. Epub 2022 Mar 10. Cell. 2022. PMID: 35344711 Free PMC article.

7

Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2.

Sun X, Yi C, Zhu Y, Ding L, Xia S, Chen X, Liu M, Gu C, Lu X, Fu Y, Chen S, Zhang T, Zhang Y, Yang Z, Ma L, Gu W, Hu G, Du S, Yan R, Fu W, Yuan S, Qiu C, Zhao C, Zhang X, He Y, Qu A, Zhou X, Li X, Wong G, Deng Q, Zhou Q, Lu H, Ling Z, Ding J, Lu L, Xu J, Xie Y, Sun B. Sun X, et al. Among authors: zhu y. Nat Microbiol. 2022 Jul;7(7):1063-1074. doi: 10.1038/s41564-022-01155-3. Epub 2022 Jun 30. Nat Microbiol. 2022. PMID: 35773398

8

Construction and efficacy testing of DNA vaccines containing HLA-A*02:01-restricted SARS-CoV-2 T-cell epitopes predicted by immunoinformatics.

Tan D, Kang N, Zhu Y, Hou J, Wang H, Xu H, Zu C, Gao Z, Liu M, Liu N, Deng Q, Lu H, Liu J, Xie Y. Tan D, et al. Among authors: zhu y. Acta Biochim Biophys Sin (Shanghai). 2024 Apr 24. doi: 10.3724/abbs.2024039. Online ahead of print. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 38655616 Free article.

9

Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2.

Gu C, Wu Y, Guo H, Zhu Y, Xu W, Wang Y, Zhou Y, Sun Z, Cai X, Li Y, Liu J, Huang Z, Yuan Z, Zhang R, Deng Q, Qu D, Xie Y. Gu C, et al. Among authors: zhu y. Sci Bull (Beijing). 2021 May 15;66(9):925-936. doi: 10.1016/j.scib.2020.12.005. Epub 2020 Dec 9. Sci Bull (Beijing). 2021. PMID: 33318880 Free PMC article.

10

Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection.

Zang J, Zhu Y, Zhou Y, Gu C, Yi Y, Wang S, Xu S, Hu G, Du S, Yin Y, Wang Y, Yang Y, Zhang X, Wang H, Yin F, Zhang C, Deng Q, Xie Y, Huang Z. Zang J, et al. Among authors: zhu y. Cell Discov. 2021 Aug 18;7(1):71. doi: 10.1038/s41421-021-00315-9. Cell Discov. 2021. PMID: 34408130 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

50,292 results

Search Page